Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Specimen Handling 40Magnetic Resonance Spectroscopy 27Carboplatin 19Gemcitabine 18Biopsy 17Cyclophosphamide 15pembrolizumab 14fludarabine 14Paclitaxel 14Cisplatin 14Oxaliplatin 12Injections 12Dexamethasone 12Radiotherapy 11Nivolumab 10Interviews as Topic 10venetoclax 8Irinotecan 8Fluorouracil 8Capecitabine 8Bevacizumab 8cemiplimab 7X-Rays 7Radiosurgery 7Bortezomib 7toripalimab 6Rituximab 6Pemetrexed 6Drug Therapy 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ravulizumab × 30 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡